Ribo Life Science key facts
- Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases.
- Ribo Life Science’s last known valuation is $1.2B (Jan 2026).
- It has raised $285.3M; the latest was IPO ($235.4M) in Jan 2026.
- Notable investors include CICC Capital, Kunshan Hi-tech Venture Capital, China Asset Management Company, Springs Capital, Ivyrock Asset Management — 12 tracked in total.
- Status: Publicly Held.
Who backs Ribo Life Science
12+- ·The complete investor list: 12 names
- ·Watch Ribo Life Science: the Monday email on marks, rounds and moves
Ribo Life Science funding rounds
No funding rounds for Ribo Life Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ribo Life Science valuation
Ribo Life Science is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.2 billion (Jan 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
Ribo Life Science investors
12 investors are on record for Ribo Life Science, including CICC Capital, Kunshan Hi-tech Venture Capital, China Asset Management Company and Springs Capital.
About Ribo Life Science
Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2007
- Employees
- 278
- Website
- ribolia.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ribo Life Science’s last known valuation, Jan 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.